Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.80 |
| ▸ | PPARG | P37231 | 3/20 | 0.80 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | PTGES | O14684 | 1/20 | 0.78 |
| ▸ | XPO1 | O14980 | 1/20 | 0.78 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | EGFR | P00533 | 1/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.78 |
| ▸ | PGR | P06401 | 1/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | RARB | P10826 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | CNR1 | P21554 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156371 | 0.94 | EPHX2 (0.82) | EPHX2PPARGCYSLTR1MEN1PTGES | |
| SCHEMBL14860949 | 0.94 | EPHX2 (0.78) | EPHX2PPARGCYSLTR1MEN1PTGES | |
| SCHEMBL13801556 | 0.93 | EPHX2 (0.76) | EPHX2PPARGCYSLTR1MEN1PTGES | |
| SCHEMBL21812553 | 0.91 | PLA2G4A (0.69) | EPHX2PPARGCYSLTR1MEN1PTGES | |
| SCHEMBL8530543 | 0.91 | — | — | |
| SCHEMBL24041199 | 0.90 | EPHX2 (0.73) | EPHX2PPARGCYSLTR1MEN1PTGES | |
| SCHEMBL8532769 | 0.89 | — | — | |
| SCHEMBL22768779 | 0.89 | EPHX2 (0.70) | EPHX2PPARGCYSLTR1 | |
| SCHEMBL4466431 | 0.89 | CYSLTR1 (1.00) | EPHX2PPARGCYSLTR1MEN1PTGES | |
| SCHEMBL13983259 | 0.89 | CYSLTR1 (0.85) | EPHX2PPARGCYSLTR1MEN1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | claimed |
| EP-2073799-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM Discovery, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| WO-2008112715-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM DISCOVERY INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
| CN-113825508-A | Composition for preventing or treating severe acute respiratory syndrome coronavirus 2 infection disease | 新泰克生物技术有限公司 | 2021-12-21 | — | — | CN | disclosed |
| US-10752585-B2 | Process for the preparation of Zafirlukast and analogs thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-08-25 | — | — | US | disclosed |
| US-20200216390-A1 | PROCESS FOR THE PREPARATION OF ZAFIRLUKAST AND ANALOGS THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-07-09 | — | — | US | disclosed |
| CN-108084077-B | Synthetic method of zafirlukast intermediate | 江汉大学 | 2020-04-14 | — | — | CN | disclosed |
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2012107364-A1 | NOVEL COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS | SCIPHARM SÀRL (LU) | 2012-08-16 | — | — | WO | disclosed |
| EP-2316468-A1 | Delivery system and methods for protecting and administering dextroamphetamine | Shire LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-1490090-A4 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | NEW RIVER PHARMACEUTICALS INC (US) | 2006-09-20 | — | — | EP | disclosed |
| US-7060708-B2 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1357928-A4 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1490090-A2 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | New River Pharmaceuticals Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| EP-1357928-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | New River Pharmaceuticals Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2003079972-A2 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | NEW RIVER PARMACEUTICALS INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003020200-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| US-5227378-A | Synergistic mixture of platelet activating factor and leukotriene antagonists | HOFFMANN-LA ROCHE INC. (US) | 1993-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752585-B2 | Process for the preparation of Zafirlukast and analogs thereof | CHUK, HRH2, CTSH | EPHX2 4144/4885PPARG 1439/4885CYSLTR1 1961/4885 |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | CACNA1G, CACNA1C, CACNA1B | EPHX2 3150/4885PPARG 3440/4885CYSLTR1 293/4885 |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | HDGF, CTSA, IAPP | EPHX2 1665/4885PPARG 2315/4885CYSLTR1 1155/4885 |
| US-20200216390-A1 | PROCESS FOR THE PREPARATION OF ZAFIRLUKAST AND ANALOGS THEREOF | CHUK, CTSH, HRH2 | EPHX2 4367/4885PPARG 1592/4885CYSLTR1 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.